VBData
动脉网
VBData appears in elsewhere's corpus as a healthcare-industry media and events platform, but the coverage is thin — no chunk gives its founding date, team, or ownership. What we can say: in spring 2024 it co-hosted, together with BlueRun Ventures, VB100, VBData-affiliated 动脉网 (VCBeat), 蛋壳研究院 and 动脉橙, a Beijing forum on peptide drugs and the industry chain around them, aimed at where peptide therapeutics would go amid a market "worth hundreds of billions" . Its consistent pairing with VB100 and VCBeat in these events suggests it sits in that healthcare-media orbit, but elsewhere's corpus does not otherwise profile the company directly.
AI-generated — may contain errors, please verify.
Coverage
Qiming Venture Partners | Connecting World-Class Science with Top Investors: Second Round of Startup Proposals Open for Inaugural S2S China Symposium
We sincerely invite top scientists to visit the S2SChina website and submit proposals, embarking on an accelerated journey from the lab to entrepreneurship.
Steady Steps Toward Renewal, Momentum Into Waves | DTX 2025 Annual Review
Those who walk deeper into the cycle always spot the next beam of light.
Qiming Venture Partners' William Hu: From 'Chasing Concepts' to 'Evaluating Global Data,' China's Pharma Innovation and Investment Logic Is Being Rebuilt
Qiming Venture Partners will continue to support the development of China's innovative pharmaceutical companies, helping Chinese innovation reach the global stage — in other words, "China Innovation, Global Value."
The Trillion-Yuan Blueprint for Peptide Drugs: From Diabetes Medication to Weight-Loss Wonder | BlueRun Ventures Biotech Forum Recap
From Pharmaceuticals to Consumer Goods: A Wave of Value Creation
BlueRun Ventures Portfolio Companies Named to 2024 Future Healthcare 100 List
Continuously searching for next-generation biotech companies that align with industry logic
With a Market Worth Hundreds of Billions, When Will Peptide Drugs Become the Next Blockbuster? | BlueRun Ventures × VBData Forum Now Open for Registration
Where Does the Hot Peptide Market Go From Here?
Multiple BlueRun Ventures portfolio companies named to 2023 Future Healthcare 100 list
Standing by founders from 0 to 1 to redefine the future.
